Life Sciences Workshop: Recent Trends in Pharmaceutical and Biotechnology Patent Law

There’s no question about it, patent practice in the pharmaceutical and biotechnology fields is becoming even more complex. We have seen many changes over the past few months in the area of patent protection in the life sciences, such as the first implementation (or lack thereof) of the Biologics Price Competition and Innovation Act (BPCIA) provisions, an increased number of IPRs involving pharmaceutical and biotech patents, the Federal Circuit’s latest word on joint infringement, changes in the Section 101 subject matter eligibility landscape, and the expansion of the doctrine of obviousness type double patenting and the consequent effect on patent term adjustment.

Please join us for an interactive discussion including:

• Joint infringement in view of the recent en banc decision by the Federal Circuit in Akamai, Section 101 subject matter eligibility, including proposals by AIPLA, IPO, and ABA for legislative reform, and the BPCIA
• Attempts by generic drug manufacturers to “skinny label” and avoid an ANDA lawsuit
• Double patenting case law and prosecution strategies for avoiding double patenting pitfalls, considering the implications of Gilead v. Natco, Searle v. Lupin, and AbbVie v. Kennedy

Due to space limitations, please register early.

Finnegan Speakers:

Jonathan R. Davies, Ph.D.
Jeffrey M. Jacobstein
Howard W. Levine
Alissa K. Lipton
Leslie A. McDonell
Sanya Sukduang

Guest Speaker:

Nathaniel S. Edwards, Ph.D., IP Counsel, Biogen

Date:

Thursday, September 17, 2015

Time:

8:30 - 9:15 a.m. – Registration and Breakfast
9:15 - 11:45 a.m. – Workshop
11:45 a.m. - 12:30 p.m. – Working Lunch
12:30 - 3:45 p.m. – Workshop

Location:

Finnegan
Two Seaport Lane
Boston, MA 02210